T cell memory, anergy and immunotherapy in breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 7, Issue 2, 2002, Pages 201-208

  Schirrmacher, Volker ^a   Feuerer, Markus ^a   Beckhove, Philipp ^a   Ahlert, Thorsten ^a,b   Umansky, Viktor ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Biotherapy Systems GmbH   (Germany)

^c Virofem Diagnostica GmbH   (Germany)

Author keywords

Bone marrow; T cell anergy; T cell immunity; T cell immunotherapy; Tumor dormancy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA A2 ANTIGEN; MUCIN 1; TUMOR VACCINE; CANCER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; BONE MARROW; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER REGRESSION; CELL DEATH; CELL STRAIN K 562; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DORMANCY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MEMORY CELL; MOUSE; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; VACCINE PRODUCTION; ANIMAL; BREAST TUMOR; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CLONAL ANERGY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 0347625432     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020308104613     Document Type: Review

References (28)

1. E. Yefenof (2001). Cancer dormancy: From observation to investigation and onto clinical intervention. Cancer Biol. 11:269-270.
2. G. L. Mansi, H. Gogas, J. M. Bliss, J. C. Gazet, U. Berger, and R. C. Coombes (1999). Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up study. Lancet 354:197-202.
3. R. Demicheli (2001). Tumor dormancy: Findings and hypotheses from clinical research on breast cancer. Cancer Biol. 11:297-305.
4. Y. Cao, M. S. O'Reilly, B. Marshall, E. Flynn, R.-W. Ji, and J. Folkman (1998). Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J. Clin. Invest. 101:1055-1063.
5. G. N. Naumov, I. C. MacDonald, A. F. Chambers, and A. C. Groom (2001). Solitary cancer cells as a possible source of tumor dormancy? Cancer Biol. 11:271-276.
6. J. D. Farrar, K. H. Katz, J. Windsor, G. Thrush, R. H. Scheuermann, J. W. Uhr, and N. E. Street (1999). Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-γ in establishing and maintaining the tumor-dormant state. J. Immunol. 162:2842-2849.
7. V. Schirrmacher (2001). T-cell immunity in the induction and maintenance of a tumor dormant state. Semin Cancer Biol. 11:285-295.
8. H. J. Schild, B. Kyewski, P. von Hoegen, and V. Schirrmacher (1987). CD4+ helper T cells are required for resistance to a highly metastatic murine tumor. Eur. J. Immunol. 17:1863-1866.
9. K. Khazaie, S. Prifti, P. Beckhove, A. Griesbach, S. Russell, M. Collins, and V. Schirrmacher (1994). Persistence of dormant tumor-cells in the bone marrow of tumor-cell-vaccinated mice correlates with long term immunological protection. Proc. Natl. Acad. Sci. 91:7430-7434.
10. M. Müller, F. Gounari, S. Prifti, H. J. Hacker, V. Schirrmacher, and K. Khazaie (1998). Eb-lacZ tumor dormancy in bone marrow and lymph nodes: Active control in proliferating tumor cells by CD8+ immune T cells. Cancer Res. 58:5439-5446.
11. T. G. Karrison, D. J. Ferguson, and P. Meier (1999). Dormancy of mammary carcinoma after mastectomy. J. Natl. Cancer Inst. 91:80-85.
12. K. Pantel, R. J. Cote, and O. Fodstad (1999). Detection and clinical importance of micrometastatic disease. J. Natl. Cancer Inst. 91:1113-1124.
13. W. Kruger, C. Krzizanowski, M. Holweg, M. Stockschlager, N. Kroger, R. Jung, K. Mross, W. Jonat, and A. R. Zander (1996). Reverse transcriptase/ polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J. Cancer Res. Clin. Oncol. 122:679-686.
14. K. Pantel and M. Otte (2001). Occult micrometastasis: Enrichment, identification and characterization of single disseminated tumor cells. Cancer Biol. 11:327-337.
15. M. Feuerer, M. Rocha, L. Bai, V. Umansky, E. F. Solomayer, G. Bastert, I. J. Diel, and V. Schirrmacher (2001). Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int. J. Cancer 92(1):96-105.
16. M. Feuerer, P. Beckhove, L. Bai, E. F. Solomayer, G. Bastert, I. J. Diel, J. Heep, M. Oberniedermayr, V. Schirrmacher, and V. Umansky (2001). Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow. Nat. Med. 7(4):452-458.
17. P. Beckhove, F. Schütz, I. J. Diel, E. F. Solomayer, G. Bastert, J. Förster, M. Oberniedermayr, M. Feuerer, L. Bai, V. Umansky, and V. Schirrmacher (in press). Efficient engraftment of human primary breast cancer transplants in NOD/SCID mice. Submitted.
18. M.-A. Perales, N. E. Blachere, M. E. Engelhorn, C. R. Ferrone, J. S. Gold, P. D. Gregor, G. Noffz, J. D. Wolchok, and A. N. Houghton (2002). Strategies to overcome immune ignorance and tolerance. Cancer Biol. 12:63-71.
19. T. Ahlert, W. Sauerbrei, G. Bastert, S. Ruhland, B. Bartik, N. Simiantonaki, J. Schumacher, B. Häcker, M. Schumacher, and V. Schirrmacher (1997). Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines. J. Clin. Oncol. 15:1354-1366.
20. V. Schirrmacher (2001). Tumor vaccines - new therapeutic approaches against cancer. Euro-Biotech(Special edn.):64-66.
21. R. Heicappell, V. Schirrmacher, P. von Hoegen, T. Ahlert, and B. Appelhans (1986). Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int. J. Cancer 37:569-577.
22. V. Schirrmacher, C. Haas, R. Bonifer, T. Ahlert, R. Gerhards, and C. Ertel (1999). Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus. Gene Ther. 6:63-73.
23. K. W. Reichard, R. M. Lorence, C. J. Cascino, M. E. Peeples, R. J. Walter, M. B. Fernando, H. M. Reyes, and J. A. Graeger (1992). Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52:448-453.
24. V. Schirrmacher, T. Ahlert, R. Heicappell, B. Appelhans, and Von Hoegen (1986). Successful application of nononcogenic viruses for antimetastatic cancer immunotherapy. Cancer Rev. 5:19-49.
25. C. Haas, C. Ertel, R. Gerhards, and V. Schirrmacher (1998). Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus. Int. J. Oncol. 13:1105-1115.
26. V. Schirrmacher, L. Bai, V. Umansky, L. Yu, Y. Xing, and Z. Qian (2000). Newcastle Disease Virus activates macrophages for antitumor activity. Int. J. Oncol. 16:363-373.
27. C. C. Termeer, V. Schirrmacher, E. B. Bröcker, and J. C. Becker (2000). Newcastle-Disease-Virus infection induces a B7-1/ B7-2 independent T-cell-costimulatory activity in human melanoma cells. Cancer Gene Ther. 7(2):316-323.
28. N. J. Nelson (1999). Scientific interest in Newcastle Disease Virus is reviving. J. Natl. Cancer Inst. 91:1708-1710.